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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S144reading method. Responders (patients with no relevant progression)
were deﬁned as those with a JSW loss between baseline and End, lower
than 0.1 mm (JSN >-0.1 mm), or 0.2 mm (JSN >-0.2 mm) or 0.3 mm
(JSN>-0.3 mm). Patients whowithdrew from the study were counted as
non-responder patients. SrRan 1g and SrRan 2g treatment groups were
compared to placebo in the FAS using a chi2 test.
Results: The ITT set included 1371 (82%) patients. Age was 637 years,
BMI was 305 kg/m2, JSW was 3.50.8 mm. 61% were KL II. 69% were
female. A statistically signiﬁcant greater proportion of patients in both
SrRan 1 g and SrRan 2 g groups were considered as responders (i.e.
preserved from a radiological progression) as compared to placebo,
when deﬁned by a JSN >-0.3 mm threshold (40.5% and 44.1% vs. 32.8%
of responders respectively, p¼0.006 and p¼0.003). In other words, the
proportion of responders compared to placebo increased by 24% and
34% in the SrRan 1g and 2g groups respectively, using a JSN >-0.3 mm
for responding deﬁnition, with a number of patients needed to be
treated (NNT) of 13 and 9 respectively. Similar differences between
groups were observed for responders at additional JSN cut-offs (i.e. JSN
>-0.1 mm or JSN >-0.2 mm):Strontium ranelate
1 g (N ¼ 445)
Strontium ranelate
2 g (N ¼ 454)
Placebo
(N ¼ 472)
Responders : JSN ‡- 0.1 mm
Patients who
responded, n (%)
130 (29.21) 136 (29.96) 101 (21.40)
p-value 0.006 0.003
RRR 36.0 40.0
NNT 13 12
Responders : JSN ‡-0.2 mm
Patients who
responded, n (%)
161 (36.18) 173 (38.11) 133 (28.18)
p-value 0.009 0.001
RRR 28.4 35.2
NNT 13 10
Responders : JSN ‡- 0.3 mm
Patients who
responded, n (%)
180 (40.5) 200 (44.05) 155 (32.80)
p-value 0.017 <0.001
RRR 23.5 34.3
NNT 13 9
RRR: relative ratio of responders vs. placebo
NNT: number of patients needed to be treatedConclusions: Treatment with SrRan is associated with a greater
number of patients preserved from OA radiological progression over 3
years.
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EFFECTS OF STRONTIUM RANELATE ON HAND OSTEOARTHRITIS.
ANALYSIS OF DATA FROM THE SEKOIA TRIAL
E. Maheu y, C. Cadet z, F. Berenbaum y. yRheumatology Dept, St Antoine
Hosp., AP-HP, Paris, Paris, France; zRheumatologist, Private practice,
Paris, France
Purpose: Strontium ranelate (SrRan) has shown the ability to reduce
radiological progression of knee osteoarthritis (OA) over 3 years.
Patients with knee OA are also frequently affected by hand OA. In this
secondary analysis, we assessed the effects of SrRan on radiological and
symptom progression of hand OA.
Methods: This international 3-year, randomized, placebo-controlled
phase III trial was designed to assess the effect of SrRan 1g and 2g/day
compared to placebo on the radiographic progression of knee OA. Main
inclusion criteria were symptomatic primary knee osteoarthritis (ACR
criteria), a Kellgren-Lawrence (KL) grade II or III, and a joint space width
(JSW) between 2.5-5 mm. There were no speciﬁc inclusion criteria
regarding hand OA. Hand OA radiographic and clinical assessments
were secondary outcomes. During the study, a baseline and ﬁnal
postero-anterior radiographs of each hand were performed. They were
graded by 2 readers, blinded to treatment and time sequence, using KL
(range 0-128), Kallman (0-204) and Verbruggen (0-218) scoring
methods. Clinical symptoms were assessed at each visit by the Auscan
(0-100) and Functional Index for Hand OA (FIHOA) (0-30). Between-group analyses were performed using a general linear model with
baseline, center and sex as covariates.
Results: Of the 1669 patients included in the SEKOIA trial, 1371 had
baseline radiographs, of whom 999 had radiologic hand OA (73%)
among which 71% were female, mean age 647 years with a body mass
index of 29.64.7 kg/m2, and initial knee JSW of 3.40.8 mm. Hand OA
was mild in severity : KL score 2113, Kallman score 2522 and Ver-
bruggen score 1415. Mean AUSCAN global score was 96+80 mm and
mean FIHOA was: 45. The radiographic progression of hand OA
observed over 3 years was modest in the placebo group with a mean
change of 2.43.3 for KL score, of 3.75.3 for Kallman score and of
2.03.9 for Verbruggen score. There was no difference between treat-
ment groups for any radiological score. A signiﬁcantly higher rate of
patients reported an improvement of 20% or more in the Auscan pain
subscore in the SrRan 2g group (95% CI [0.1; 16.3] p¼0.047) compared to
placebo. In erosive patients (2 erosive joints, N¼71), a signiﬁcant
improvement of KL score (p¼0.031) in the SrRan 2g compared to
placebo was observed. In symptomatic patients (having a FIHOA>5 and
pain within the 48 hours prior to the visit, N¼126), a trend toward
a higher improvement of KL score was noted in the SrRan 2g group
compared to placebo (p¼0.079).
Conclusions: Overall, mild hand OA patients had a low radiological
progression, with no between-group difference over 3 years. However,
in subgroup analyses, a slight beneﬁcial effect of strontium ranelate 2g
could be observed on pain and a positive effect of strontium ranelate 2g
was suggested on the variation of the KL score in the more severe hand
OA patients. These results encourage to perform in the future a speciﬁc
trial in hand OA.267
FX006 PROLONGS THE RESIDENCY OF TRIAMCINOLONE ACETONIDE
IN THE SYNOVIAL TISSUES OF PATIENTS WITH KNEE
OSTEOARTHRITIS
N. Bodick y, J. Lufkin y, C. Willwerth y, R.C. Blanks y, C.A. Inderjeeth z,x,
A. Kumar y, M.D. Clayman y. y Flexion Therapeutics, Woburn, MA, USA;
z Linear Clinical Res. Limited, Perth, Australia; xUniv. of Western
Australia, Perth, Australia
Purpose: Intra-articular (IA) administration of triamcinolone acetonide
injectable suspension (TCA IR) is commonly used to treat pain and
inﬂammation associatedwithosteoarthritis (OA)of theknee. FX006 is an
extended-release IA formulation of TCA in poly(lactic-co-glycolic acid)
(PLGA) microspheres that is intended to deliver TCA to the synovial and
peri-synovial tissues for a period of up to 3months. The purposes of this
study included the evaluation of safety and tolerability and the char-
acterization of pharmacokinetics (PK) and pharmacodynamics (PD) of
FX006 relative to TCA IR.
Methods: In this double blind, randomized, parallel group, active
comparator study, 24 patients were randomized (1:1:1:1) to receive
a single IA injection of 10mg, 40mgor 60mgof FX006or 40mgof TCA IR.
Each patient was followed for 6 weeks. Safety, PK and PD were evalu-
ated during three in-patient periods and seven out-patient visits.
Results: As expected, injection of TCA IR produced high peak plasma
concentrations within hours of administration, which dropped rapidly
over the ensuing 7 days (Figure 1). IA administration of FX006 produced
a distinctly different proﬁle; peak concentrations were achieved
approximately 24h after injection, remained constant over the 4 days
post injection and thereafter declined slowly (Figures 1 and 2). The Cmax
associated with 40 mg TCA IR was nearly 30-fold that observed with 40
mg FX006, and the exposure over the ﬁrst 24h (AUC0-24) was 21-fold
higher. The total exposure (AUC0-inf) to TCA with 40 mg TCA IR was 2-
fold greater than that achieved with 40 mg FX006. Synovial ﬂuid
concentration measurements of (non-encapsulated) TCA demonstrated
a 200 to 500-fold multiple over corresponding plasma levels for all
doses of FX006 at Day 43. TCA was not measureable at Day 43 in the
synovial ﬂuid of patients that received 40 mg TCA IR. All treatments
were well tolerated. There were no serious adverse events or discon-
tinuations due to an adverse event (AE). The majority of AEs were mild
and considered unrelated to study drug. Local knee-related AEs were
also similar across treatments. Laboratory assessments, ECGs and vital
signs were unremarkable and similar across all treatments.
Conclusions: FX006 maintains a gradient between synovial and
systemic concentrations for the duration of this 6-week study. Even at
the lowest dose of FX006, synovial concentrations of TCA are consistent
with biologic activity at 6 weeks; at this time point, the synovial
